Prolonged QRS duration in lead V2 and risk of Life-Threatening ventricular arrhythmia in patients with brugada syndrome

International Heart Journal

Volumn 52, Issue 2, 2011, Pages 98-102

  Ohkubo, Kimie ^a   Watanabe, Ichiro ^a   Okumura, Yasuo ^a   Ashino, Sonoko ^a   Kofune, Masayoshi ^a   Nagashima, Koichi ^a   Kofune, Tatsuya ^a   Nakai, Toshiko ^a   Kunimoto, Satoshi ^a   Kasamaki, Yuji ^a   Hirayama, Atsushi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Brugada syndrome; QRS width; Sudden death; Ventricular fibrillation

Indexed keywords

ADULT; AGED; ARTICLE; BRUGADA SYNDROME; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; HEART ARREST; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HIGH RISK PATIENT; HUMAN; MALE; NON INVASIVE PROCEDURE; PR INTERVAL; PREDICTION; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RISK ASSESSMENT; SIGNAL PROCESSING; SUDDEN DEATH; SYNCOPE;

ADULT; AGED; BRUGADA SYNDROME; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; HEART CONDUCTION SYSTEM; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VENTRICULAR FIBRILLATION;

EID: 79954507309     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.52.98     Document Type: Article

References (32)

1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992; 20: 1391-6.
2. Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998; 97: 457-60.
3. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111: 659-70. (Review)
4. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392: 293-6.
5. Antzelevitch C, Brugada P, Brugada J, Brugada R, Towbin JA, Nademanee K. Brugada syndrome: 1992-2002: a historical perspective. J Am Cardiol 2003; 41: 1665-71. (Review)
6. London B, Michalec M, Mehdi H, et al. Mutation in glycerol-3- phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 2007; 116: 2260-8.
7. Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115: 442-9.
8. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996; 27: 1061-70.
9. Antzelevitch C, Brugada R. Fever and Brugada syndrome. Pacing Clin Electrophysiol 2002; 25: 1537-9. (Review)
10. Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 2002; 106: 2514-9. (Review)
11. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003; 108: 3092-6.
12. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002; 105: 1342-7.
13. Gehi AK, Duong TD, Metz LD, Gomes JA, Mehta D. Risk stratification of individuals with the Brugada electrocardiogram: a meta- analysis. J Cardiovasc Electrophysiol 2006; 17: 577-83.
14. Eckardt L, Probst V, Smits JP, et al. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation 2005; 111: 257-63.
15. Glatter KA, Chiamvimonvat N, Viitasalo M, Wang Q, Tuteja D. Risk stratification in Brugada syndrome. Lancet 2005; 366: 530-1.
16. Benito B, Sarkozy A, Mont L, et al. Gender differences in clinical manifestations of Brugada syndrome. J Am Coll Cardiol 2008; 52: 1567-73.
17. Kamakura S, Ohe T, Nakazawa K, et al. Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1-V3. Circ Arrhythm Electrophysiol 2009; 2: 495-503.
18. Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada Syndrome Registry. Circulation 2010; 121: 635-43.
19. Ikeda T, Takami MM, Sugi K, Mazusawa Y, Sakurada H, Yoshino H. Noninvasive risk stratification of subjects with a Brugada-type electrocardiogram and no history of cardiac arrest. Ann Noninvasive Electrocardiol 2005; 10: 396-403.
20. Tatsumi H, Takagi M, Nakagawa E, Yamashita H, Yoshiyama M. Risk stratification in patients with Brugada syndrome: analysis of daily fluctuations in 12-lead electrocardiogram (ECG) and signalaveraged electrocardiogram (SAECG). J Cardiovasc Electrophysiol 2006; 17: 705-11.
21. Castro Hevia J, Antzelevitch C, Tornés Bárzaga F, et al. Tpeak- Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol 2006; 47: 1828-34.
22. Morita H, Kusano KF, Miura D, et al. Fragmented QRS as a marker of conduction abnormality and a predictor of Brugada syndrome. Circulation 2008; 118: 1697-704.
23. Ikeda T, Sakurada H, Sakabe K, et al. Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: insight into risk stratification. J Am Coll Cardiol 2001; 37: 1628-34.
24. Ajiro Y, Hagiwara N, Kasanuki H. Assessment of markers for identifying patients at risk for life-threatening arrhythmic events in Brugada syndrome. J Cardiovasc Electrophysiol 2005; 16: 45-51.
25. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000; 101: 510-5.
26. Evain S, Briec F, Kyndt F, et al. Sodium channel blocker tests allow a clear distinction of electrophysiological characteristics and prognosis in patients with a type 2 or 3 Brugada electrocardiogram pattern. Heart Rhythm 2008; 5: 1561-4.
27. Morita H, Morita ST, Nagase S, et al. Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol 2003; 42: 1624-31.
28. Chinushi M, Komura S, Izumi D, et al. Incidence and initial characteristics of pilsicainide-induced ventricular arrhythmias in patients with Brugada syndrome. Pacing Clin Electrophysiol 2007; 30: 662-71.
29. Atarashi H, Ogawa S; Idiopathic Ventricular Fibrillation Investigators. New ECG criteria for high-risk Brugada syndrome. Circ J 2003; 67: 8-10.
30. Takagi M, Yokoyama Y, Aonuma K, et al. Clinical characteristics and risk stratification in symptomatic and asymptomatic patients with brugada syndrome: multicenter study in Japan. J Cardiovasc Electrophysiol 2007; 18: 1244-51.
31. Junttila MJ, Brugada P, Hong K, et al. Differences in 12-lead electrocardiogram between symptomatic and asymptomatic Brugada syndrome patients. J Cardiovasc Electrophysiol 2008; 19: 380-3.
32. Huang Z, Patel C, Li W, et al. Role of signal-averaged electrocardiograms in arrhythmic risk stratification of patients with Brugada syndrome: a prospective study. Heart Rhythm 2009; 6: 1156-62.